Seroatlas · Human Serome Atlas

B4GALT7

Beta-1,4-galactosyltransferase 7

Also known as: B4GT7_HUMAN, beta4Gal-T7, XGALT-1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9UBV7
Gene
B4GALT7
Ensembl
ENSG00000027847
Chromosome
5
Canonical length
327 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins

OverviewNCBI Gene

This gene is a member of the beta-1,4-galactosyltransferase (beta4GalT) family. Family members encode type II membrane-bound glycoproteins that appear to have exclusive specificity for the donor substrate UDP-galactose. Each beta4GalT member has a distinct function in the biosynthesis of different glycoconjugates and saccharide structures. As type II membrane proteins, they have an N-terminal hydrophobic signal sequence that directs the protein to the Golgi apparatus which then remains uncleaved to function as a transmembrane anchor. The enzyme encoded by this gene attaches the first galactose in the common carbohydrate-protein linkage (GlcA-beta1,3-Gal-beta1,3-Gal-beta1,4-Xyl-beta1-O-Ser) found in proteoglycans. This enzyme differs from other beta4GalTs because it lacks the conserved Cys residues found in beta4GalT1-beta4GalT6 and it is located in cis-Golgi instead of trans-Golgi. Mutations in this gene have been associated with the progeroid form of Ehlers-Danlos syndrome. [provided by RefSeq, Oct 2009]

Canonical amino-acid sequenceUniProt

327 residues, UniProt reviewed canonical sequence.

>Q9UBV7|B4GALT7
     1  MFPSRRKAAQ LPWEDGRSGL LSGGLPRKCS VFHLFVACLS LGFFSLLWLQ LSCSGDVARA
    61  VRGQGQETSG PPRACPPEPP PEHWEEDASW GPHRLAVLVP FRERFEELLV FVPHMRRFLS
   121  RKKIRHHIYV LNQVDHFRFN RAALINVGFL ESSNSTDYIA MHDVDLLPLN EELDYGFPEA
   181  GPFHVASPEL HPLYHYKTYV GGILLLSKQH YRLCNGMSNR FWGWGREDDE FYRRIKGAGL
   241  QLFRPSGITT GYKTFRHLHD PAWRKRDQKR IAAQKQEQFK VDREGGLNTV KYHVASRTAL
   301  SVGGAPCTVL NIMLDCDKTA TPWCTFS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against B4GALT7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Other membrane
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.34
Highest tissue expression
43 nTPM

Expression across tissuesHPA

Tissue

  • adrenal gland: 43 nTPM
  • choroid plexus: 38 nTPM
  • pancreas: 36 nTPM
  • pituitary gland: 31 nTPM
  • liver: 30 nTPM
  • testis: 24 nTPM

Single-cell type

  • extravillous trophoblasts: 186 nCPM
  • migrating cytotrophoblasts: 55 nCPM
  • plasma cells: 53 nCPM
  • cytotrophoblasts: 51 nCPM
  • decidual stromal cells: 46 nCPM
  • syncytiotrophoblasts: 44 nCPM

Immune cell

  • intermediate monocyte: 20 nTPM
  • non-classical monocyte: 20 nTPM
  • myeloid DC: 19 nTPM
  • naive B-cell: 19 nTPM
  • basophil: 17 nTPM
  • classical monocyte: 17 nTPM

Brain region

  • midbrain: 46 nTPM
  • pons: 46 nTPM
  • medulla oblongata: 45 nTPM
  • thalamus: 39 nTPM
  • choroid plexus: 39 nTPM
  • hypothalamus: 39 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about B4GALT7.

Disease | AllUniProt

Conditions B4GALT7 is implicated in, by any mechanism.

Disease | GeneticClinVar

25 pathogenic / likely-pathogenic of 450 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.11
gnomAD pLI
0
gnomAD missense Z
-0.31
DepMap mean gene effect
-0.06
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads B4GALT7 as an antibody target. Whether an autoantibody or antibody against B4GALT7 could matter depends on whether native B4GALT7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

B4GALT7 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label B4GALT7 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/B4GALT7. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...